



## **ZIM Laboratories Limited and Neuraxpharm enter into an exclusive co-development agreement in Europe for novel drug delivery system**

**Nagpur, March 25, 2019:** ZIM Laboratories Limited, a specialty pharma R&D company focused on a novel drug delivery system, today announced that it has signed an exclusive agreement in Europe with Neuraxpharm, a European specialty pharmaceutical company focusing on central nervous system (CNS) disorders. The agreement is for the co-development and commercialization of novel oral thin films (OTF) based products with ZIM Laboratories' patented technology.

As per the agreement, ZIM Laboratories Limited will develop a novel delivery system in the form of OTF for a molecule, to be used as opioid substitution treatment in illicit drug dependant patients. This unique delivery system, developed by ZIM Laboratories' patented OTF technology, will address medical needs of physicians and patients which are currently not being served. The new delivery system will enhance patient convenience and, at the same time, will be preferred by the regulators for its unique features.

Commenting on the development, **Dr. Anwar Daud, Chairman & Managing Director, ZIM Laboratories** said, "I am very happy that our patented OTF technology is getting global recognition and acceptance. The co-development agreement with Neuraxpharm is a step towards ZIM Laboratories' global aspirations of becoming a preferred partner globally for new drug delivery systems."

**Dr. Jörg-Thomas Dierks, Chief Executive Officer of Neuraxpharm**, said: "We are very pleased to partner with ZIM Laboratories to develop this novel drug delivery system. Oral thin films have the potential to improve the compliance and the safety of the medication of patients by better avoiding a misuse of the drug".

The growing market size for the molecule in Europe is more than 120 million Euro.

### **About ZIM Laboratories Limited**

Zim is a pharmaceutical company focused on providing innovative drug delivery solutions that improve convenience and adherence of drug treatment. Zim acts as a research centric product development partner for its customers across several Pharmerging and ROW markets by providing a constant pipeline of therapy agnostic finished and semi-finished pharmaceutical formulation products, using proprietary novel drug delivery solutions.

### **About Neuraxpharm**

Neuraxpharm is a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders with a direct presence in Germany, Spain, Italy, France, United Kingdom, Poland, Czech Republic, Slovakia and Hungary. With a unique understanding of the CNS market built over 30 years, Neuraxpharm develops and commercializes in Europe branded and generic CNS pharmaceuticals, as well as nutraceuticals and probiotics, offering a wide range of effective, differentiated and affordable CNS treatments. <https://www.neuraxpharm.com/>

**For more information, contact**

**Ankita Sircar – [ankitasircar@dickensonir.com](mailto:ankitasircar@dickensonir.com)**

**Dickenson IR**